GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (14)
  • Fu, Rong  (14)
  • 2020-2024  (14)
Material
Publisher
  • Wiley  (14)
Language
Years
  • 2020-2024  (14)
Year
FID
Subjects(RVK)
  • 1
    In: Journal of Clinical Laboratory Analysis, Wiley, Vol. 36, No. 2 ( 2022-02)
    Abstract: We performed a retrospective analysis to investigate the clinical characteristics and therapeutic strategies of 20 refractory/recurrent PNH patients, including the clinical efficacy of chemotherapy treatment, safety, and survival. Methods The clinical data of 20 classic PNH patients who were refractory/recurrent or had glucocorticoid dependence in our hospital were analyzed, including clinical manifestations, laboratory examinations, treatment efficacy, and survival. Results Seventeen patients had a marked improvement in anemia after chemotherapy, 14 patients acquired blood transfusion independence, and the Hb of 3 patients increased to normal levels. Although 6 patients still needed blood transfusion, the transfusion interval was significantly prolonged. The percentages of LDH, TBIL, and RET, which are indicators of hemolysis, were significantly lower than those before chemotherapy. The dosage of adrenal glucocorticoids was reduced by more than half compared with that before chemotherapy. Conclusions Chemotherapy can reduce PNH clones, promote normal hematopoiesis, and control hemolytic attack. It is a promising and widely used therapeutic method.
    Type of Medium: Online Resource
    ISSN: 0887-8013 , 1098-2825
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2001635-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Wiley ; 2023
    In:  International Journal of Cancer Vol. 153, No. 8 ( 2023-10-15), p. 1436-1447
    In: International Journal of Cancer, Wiley, Vol. 153, No. 8 ( 2023-10-15), p. 1436-1447
    Abstract: Multiple myeloma ( MM ) is a relapsing clonal plasma cell malignancy and incurable thus far. With the increasing understanding of myeloma, highlighting the critical importance of the immune system in the pathogenesis of MM is essential. The immune changes in MM patients after treatment are associated with prognosis. In this review, we summarize currently available MM therapies and discuss how they affect cellular immunity. We find that the modern anti‐MM treatments enhance antitumour immune responses. A deeper understanding of the therapeutic activity of individual drugs offers more effective treatment approaches that enhance the beneficial immunomodulatory effects. Furthermore, we show that the immune changes after treatment in MM patients can provide useful prognostic marker. Analysing cellular immune responses offers new perspectives for evaluating clinical data and making comprehensive predictions for applying novel therapies in MM patients.
    Type of Medium: Online Resource
    ISSN: 0020-7136 , 1097-0215
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 218257-9
    detail.hit.zdb_id: 1474822-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Wiley ; 2022
    In:  British Journal of Pharmacology Vol. 179, No. 11 ( 2022-06), p. 2659-2677
    In: British Journal of Pharmacology, Wiley, Vol. 179, No. 11 ( 2022-06), p. 2659-2677
    Abstract: The zinc finger transcription factor Snail is aberrantly activated in many human cancers and strongly associated with poor prognosis. As a transcription factor, Snail has been traditionally considered an ‘undruggable’ target. Here, we identified a potent small‐molecule inhibitor of Snail, namely trimethoprim, and investigated its potential antitumour effects and the underlying mechanisms. Experimental Approach The inhibitory action of trimethoprim on Snail protein and the related molecular mechanisms were revealed by molecular docking, biolayer interferometry, immunoblotting, immunoprecipitation, qRT‐PCR, pull‐down and cycloheximide pulse‐chase assays. The anti‐proliferative and anti‐metastatic effects of trimethoprim via targeting Snail were tested in multiple cell‐based assays and animal models. Key Results This study identified trimethoprim, an antimicrobial drug, as a potent antitumour agent via targeting Snail. Molecular modelling analysis predicted that trimethoprim directly binds to the arginine‐174 pocket of Snail protein. We further discovered that trimethoprim strongly interrupts the interaction of Snail with CREB‐binding protein (CBP)/p300, which consequently suppresses Snail acetylation and promotes Snail degradation through the ubiquitin‐proteasome pathway. Furthermore, trimethoprim sufficiently inhibited the proliferation, epithelial–mesenchymal transition (EMT) and migration of cancer cells in vitro via specifically targeting Snail. More importantly, trimethoprim effectively reduced Snail‐driven tumour growth and metastasis to vital organs such as lung, bone and liver. Conclusions and Implications These findings indicate, for the first time, that trimethoprim suppresses tumour growth and metastasis via targeting Snail. This study provides insights for a better understanding of the anticancer effects of trimethoprim and offers a potential anticancer therapeutic agent for clinical treatment.
    Type of Medium: Online Resource
    ISSN: 0007-1188 , 1476-5381
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2029728-2
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Wiley ; 2023
    In:  CNS Neuroscience & Therapeutics Vol. 29, No. S1 ( 2023-06), p. 185-199
    In: CNS Neuroscience & Therapeutics, Wiley, Vol. 29, No. S1 ( 2023-06), p. 185-199
    Abstract: Stroke is not only a major cause of disability but also the third leading cause of death, following heart disease and cancer. It has been established that stroke causes permanent disability in 80% of survivors. However, current treatment options for this patient population are limited. Inflammation and immune response are major features that are well‐recognized to occur after a stroke. The gastrointestinal tract hosts complex microbial communities, the largest pool of immune cells, and forms a bidirectional regulation brain‐gut axis with the brain. Recent experimental and clinical studies have highlighted the importance of the relationship between the intestinal microenvironment and stroke. Over the years, the influence of the intestine on stroke has emerged as an important and dynamic research direction in biology and medicine. Aims In this review, we describe the structure and function of the intestinal microenvironment and highlight its cross‐talk relationship with stroke. In addition, we discuss potential strategies aiming to target the intestinal microenvironment during stroke treatment. Conclusion The structure and function of the intestinal environment can influence neurological function and cerebral ischemic outcome. Improving the intestinal microenvironment by targeting the gut microbiota may be a new direction in treating stroke.
    Type of Medium: Online Resource
    ISSN: 1755-5930 , 1755-5949
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2423467-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Medicine, Wiley, Vol. 12, No. 13 ( 2023-07), p. 13885-13893
    Abstract: The hypomethylating agent decitabine is the standard therapy for intermediate or high risk myelodysplastic syndrome (MDS). Methods In this trial, 191 adult patients with intermediate/high risk MDS (IPSS score ≥ 0.5) randomly received decitabine using a standard regimen (20 mg/m 2 /day for 5 consecutive days; n  = 94) or an extended regimen with lower daily dose (12 mg/m 2 /day for 8 consecutive days; n  = 97) every 4 weeks, for a total of 4 cycles. Results The median follow‐up was 14 months (range 2–36). The primary end point of overall response rate in the intent‐to‐treat analysis was 41.5% and 38.1% in the standard and extended dosing arms, respectively ( p  = 0.660). Complete remission and marrow complete remission also did not differ between the two arms. Cytopenia was the most frequent adverse event (76.4%). The median duration of neutropenia per cycle did not differ between the two arms during the first two cycles, but significantly shorter in the extended dosing arm in the third cycle (8.5 vs. 15.5 days, p  = 0.049) and in the fourth cycle (8 vs. 14 days, p  = 0.294). Conclusion The 5‐day 20‐mg/m 2 /day and 8‐day 12‐mg/m 2 /day decitabine regimens have similar efficacy and safety in patients with intermediate or high risk MDS.
    Type of Medium: Online Resource
    ISSN: 2045-7634 , 2045-7634
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2659751-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Clinical and Translational Medicine, Wiley, Vol. 13, No. 3 ( 2023-03)
    Type of Medium: Online Resource
    ISSN: 2001-1326 , 2001-1326
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2697013-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: British Journal of Pharmacology, Wiley, Vol. 177, No. 18 ( 2020-09), p. 4166-4180
    Abstract: Hepatic fatty acid metabolism disorder, a key pathogenic mechanism underlying non‐alcoholic fatty liver disease (NAFLD), is associated with the hyperacetylation of mitochondrial enzymes. Acyl‐CoA synthetase family member 3 (ACSF3), which is involved in the regulation of fatty acid metabolism, was predicted to contain lysine acetylation sites related to the mitochondrial deacetylase sirtuin 3 (SIRT3). The purpose of this study was to explore the underlying mechanism by which SIRT3 deacetylates ACSF3 in NAFLD and the protective effect of the natural phenolic compound protocatechuic acid (PCA) against fatty acid metabolism disorder via the SIRT3/ACSF3 pathway. Experimental Approach The role of protocatechuic acid and its molecular mechanism in NAFLD were detected in rats and SIRT3‐knockout mice fed a high‐fat diet (HFD) and in AML‐12 cells treated with palmitic acid (PA). Key Results Pharmacological treatment with protocatechuic acid significantly attenuated high‐fat diet‐induced fatty acid metabolism disorder in NAFLD. Molecular docking assays showed that protocatechuic acid specifically bound SIRT3 as a substrate and increased SIRT3 protein expression. However, the protective role of protocatechuic acid was abolished by SIRT3 knockdown, which increased ACSF3 expression and exacerbated fatty acid metabolism disorder. Mechanistically, SIRT3 was shown to specifically regulate the acetylation and degradation of ACSF3, which govern the capacity of ACSF3 to mediate fatty acid metabolism disorder during NAFLD. Conclusion and Implications SIRT3‐mediated ACSF3 deacetylation is a novel molecular mechanism in NAFLD therapy and protocatechuic acid confers protection against high‐fat diet‐ and palmitic acid‐induced hepatic fatty acid metabolism disorder through the SIRT3/ACSF3 pathway.
    Type of Medium: Online Resource
    ISSN: 0007-1188 , 1476-5381
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2029728-2
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: British Journal of Pharmacology, Wiley
    Abstract: The scaffold molecule Axin2 is constitutively activated in colorectal cancer (CRC) and functions as a potent promoter of CRC behaviour. Pharmacological targeting of Axin2 may therefore exert a therapeutic effect in patients with CRC. Here, we discovered a potent small‐molecule inhibitor of Axin2, based on the mechanism by which Axin2 is regulated post‐translationally, and investigated its antitumour effects. Experimental Approach Compound discovery and its inhibitory action on Axin2 protein were revealed by microscale thermophoresis, in vitro kinase assay, quantitative kinetic assay, immunoblotting/immunoprecipitation, RT‐qPCR and cycloheximide pulse‐chase assay. Compound antitumour effects and the underlying mechanisms were evaluated in multiple cell‐based assays and mouse models. Key Results We discovered that glycogen synthase kinase 3β (GSK3β) phosphorylates Axin2 at two consensus motifs and coupled Axin2 phosphorylation to its ubiquitination (mediated by the E3 ligase β‐Trcp2) and proteasomal degradation. The binding of Axin2 to GSK3β in CRC cells is faint, which enables most of the Axin2 protein to maintain an unphosphorylated status and thereby permits the cells to preserve high levels of Axin2. Importantly, we identified a small‐molecule compound CW85319 that enhances Axin2's interaction with GSK3β via forming a high affinity for Axin2. Treatment of CRC cells with CW85319 enhanced Axin2 binding with GSK3β, thereby promoting Axin2 phosphorylation, subsequent ubiquitination, and degradation. Furthermore, we demonstrated that CW85319 efficiently suppressed Axin2‐driven CRC growth and metastasis, without eliciting side toxicity. Conclusions and Implications These findings suggest that pharmacological targeting of Axin2 by CW85319 may provide therapeutic benefits against certain human cancers, especially CRC.
    Type of Medium: Online Resource
    ISSN: 0007-1188 , 1476-5381
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2029728-2
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Clinical and Translational Medicine, Wiley, Vol. 12, No. 7 ( 2022-07)
    Type of Medium: Online Resource
    ISSN: 2001-1326 , 2001-1326
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2697013-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Advanced Functional Materials, Wiley, Vol. 33, No. 37 ( 2023-09)
    Abstract: Transition‐metal based layered doubled hydroxides (LDH) as oxygen evolution reaction (OER) catalysts have attracted tremendous research interests. However, it is still a great challenge to strengthen the intrinsic activity of LDH. Herein, hollow CoNiFe‐LDH nanocages with amorphous/crystal phase and element gradient distribution are successfully constructed through the coordinated etching and precipitation process. Utilizing the difference of solubility product constants among transition metal cations to generate the gradient distribution effect in nanocages is proposed for the first time. The distinctive element gradient distribution in hollow CoNiFe‐LDH nanocages results in the composition gradient, which can provide the heterojunctions effect and play an important role in regulating morphology and electronic structure. Density functional theory calculations disclose that the synergistic effect between elements significantly regulates the electron density and enhances the conductivity. When employed as OER electrocatalysts, it exhibits a very competitive overpotential of 257 mV at 10 mA cm −2 combined with a low Tafel slope of 31.4 mV dec −1 . This work represents a promising strategy to fabricate highly efficient OER catalysts for electrochemical water splitting and provides new opportunities to understand the promotion mechanism of intrinsic activity.
    Type of Medium: Online Resource
    ISSN: 1616-301X , 1616-3028
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2029061-5
    detail.hit.zdb_id: 2039420-2
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...